The Delaware Comprehensive Sickle Cell Research Center

项目总结 特拉华镰状细胞病(SCD)科布雷是一个多学科的生物医学研究中心 卓越，以镰状细胞疾病的翻译、临床和心理社会研究为主题。 建立在通过Cobre第一阶段资金开发的生物医学和临床研究基础设施上，以及 在成功招聘了几名有前途的早期职业调查人员后，DE SCD Cobre正在提交一份 竞争续展申请，以继续能力建设和创新研究。在第一阶段，DE SCD 科布雷在特拉华州贡献了1300多万美元的新资金。DE SCD Cobre的整合 在特拉华州，IDEA网络继续是成功招聘和培训 早期职业调查人员，以及飞行员资金。在这份第二阶段的Cobre提交中，DE SCD Cobre 提出新的指导模式、新的试点资助计划、新的临床研究和数据信息学 核心和四个新的目标调查人员。这些新增加的每一个都建立在第一阶段的成功基础上，并且 对优势和增长领域作出反应。此外，我们还开发了一个多学科的、系统的 研究社区和保健系统内的耻辱和种族主义对 SCD患者常规健康维护和针对性干预的效果。我们将评估 严重SCD合并症的生物标记物(项目4)，让我们的患者和社区评估 常规护理的障碍(项目1、2和3)，并探索在卫生保健中提高自我效能的工具 提供者(项目1)和患者(项目1、2和3)，同时面临种族主义的影响 儿童和年轻人的健康(项目1、2和3)。特拉华州镰刀细胞的所有方面的中心 研究计划是压倒一切的中心假设，即有效管理一个共同的、 先天性的，多系统的疾病需要全面的研究，包括生物学，医学， 影响疾病严重程度和干预效果的心理和社会因素。

PROJECT SUMMARY The Delaware Sickle Cell Disease (SCD) COBRE is a multidisciplinary center of biomedical research excellence with a thematic focus on translational, clinical and psychosocial research in sickle cell disease. Building on a biomedical and clinical research infrastructure developed through COBRE Phase 1 funding, and the successful recruitment of several promising early career investigators, the DE SCD COBRE is submitting a competitive renewal application to continue capacity-building and innovative research. In Phase 1, the DE SCD COBRE contributed to more than $13 million in new funding in Delaware. Integration of the DE SCD COBRE within the Delaware IDeA network continues to be integral to both the successful recruitment and training of early career investigators, as well as pilot funding. In this Phase 2 COBRE submission, the DE SCD COBRE presents a new mentoring model, a new pilot funding program, a new Clinical Research and Data Informatics Core and four new target investigators. Each of these new additions builds on success in Phase 1 and is responsive to areas of strength and growth. Additionally, we developing a multidisciplinary and systematic approach to study the influence of stigma and racism within communities and the healthcare system on the efficacy of both routine health maintenance and targeted interventions in patients with SCD. We will evaluate biomarkers for severe SCD co-morbidities (Project 4), engage our patients and community to take stock of barriers to routine care (Project 1, 2, and 3) and explore tools to improve self-efficacy among health care providers (Project 1) and patients (Project 1, 2, and 3), while simultaneously confronting how racism impacts the health of children and young adults (Project 1, 2, and 3). Central to all aspects of the Delaware Sickle Cell Research Program is the overarching Center hypothesis that effective management of a common, congenital, multi-system disease requires comprehensive investigations spanning the biological, medical, psychological, and societal factors that impact both the severity of the disease and the efficacy of interventions.